Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 15, 2021

Coronavirus company news summary – EMA starts rolling submission of CureVac Covid-19 vaccine – RECOVERY trial finds tocilizumab to reduce risk of death in hospitalized patients

By Allie Nawrat

15 February 2021

CureVac has announced the European Medicines Agency (EMA) has begun a rolling submission of CVnCoV, the company’s mRNA-based Covid-19 vaccine candidate. The EMA’s rolling submission will accelerate time to potential marketing authorisation of CVnCoV.

Moderna announced that the company has received an additional order of four million doses of the Covid-19 vaccine from the Canadian Government, bringing the total commitment order to 44 million doses. Health Canada authorised Moderna’s Covid-19 vaccine for immunising people aged over 18 at the end of December 2020.

A new UK trial has found the arthritis drug tocilizumab reduces the risk of death among hospitalised Covid-19 patients. The RECOVERY trial also found that the drug helped reduce the need for ventilation support.

The US Government has exercised its option for an additional 100 million doses of the PfizerBioNTech Covid-19 Vaccine, bringing the total vaccine doses to 300 million . The US government is expected to pay $1.95bn for the additional vaccine doses.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU